Symbol
| TPM2
| contributors: mct/npt - updated : 09-05-2018
|
HGNC name
| tropomyosin 2 (beta)
|
HGNC id
| 12011
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
constitutional
|  
|  
|  
| loss of function
|
impaired the differentiation of MSCs by significant reduction of adipogenesis and osteogenesis | |
Variant & Polymorphism
|
| |
Candidate gene
Marker
Therapy target
|
System | Type | Disorder | Pubmed |
neuromuscular | myopathy | congenital | |
administration of troponin activators may constitute a promising therapeutic approach to minimize generalized skeletal muscle weakness in Nemaline myopathy | cancer | reproductive | breast | |
may represent a promising therapeutic gene target for breast cancer patients with chemoresistance |
| | | |
| among the Tpm2 mutations associated with skeletal myopathies, the Tpm2E122K mutation was found to reduce Tpm2 expression and impair spatial learning and memory in rats |